Back to Directory
Investigational oral ketamine formulations for treatment-resistant depression
Neurocentrx Pharma is a clinical-stage biopharmaceutical company developing oral ketamine formulations for treatment-resistant mood disorders.
Its NRCx-201 programme includes immediate-release and abuse-deterrent capsules intended for clinically supervised treatment and potentially supported home care. Following completed Phase 1 human studies, the company is pursuing further clinical evaluation in treatment-resistant depression and bipolar depression. It is also developing digital prescription-safety tools designed to support monitoring, clinical oversight and continuity of care.